Sashi S. Kommu

East Kent Hospitals University NHS Foundation Trust

Dr Sashi S. Kommu is an Associate Professor in Uro-oncology and Cancer Biology in The School of Biosciences; The University of Kent, United Kingdom. He is also a Consultant Pelvic Cancer Urological Surgeon with a subspecialty interest in minimally invasive management of urological cancers including laparoscopic and robotic urological surgery at East Kent Hospitals University NHS Foundation Trust. He leads The National Institute for Health Research (NIHR) for all surgical specialties for Kent, Surrey and Sussex in the U.K. His key clinical interests are in the minimally invasive management of urological cancers, surgical robotics and intelligent probes. He has done formal research at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research with The Translational Cancer Genetics Team where he refined his scientific methodology in advanced laboratory work with an emphasis on cancer genetics and proteomics. He has also gained vast exposure in nanotechnology. He has over 100 peer-reviewed publications in respected scientific and medical journals including The Lancet. He also has over 300 scientific presentations, several book chapters and books. Dr Kommu has over 25 academic awards including The Olympus Award at The 25th World Congress of Endourology in Cleveland U.S.A. 2006. He has nine pending patents including a cost-effective Telerounding Kit for Remote Teleconsultations, which was presented at The House of Commons (Hosted by The British Parliament) in 2006. His ability to blend medical science with engineering and technology has earned him two NASA collaborative scientific commendations. Dr Kommu is reviewer for 15 surgical/urological and 3 basic sciences journals. Several novel concepts described by Dr Kommu include ‘suppressor screening in urological cancer screening’ and ‘the supplementary biomarker approach’ for detecting cancers.

3books edited

1chapters authored

Latest work with IntechOpen by Sashi S. Kommu

Kidney cancer imposes a significant cancer burden and its incidence continues to rise globally. Mortality in advanced kidney cancer remains high despite oncological, surgical and multimodal optimisation. Genetic associations, heterogeneity and limitations in early diagnosis through lack of optimal biomarkers add to the challenges. Over the last two decades there has been an exponential increase in diagnostic and therapeutic advances in the management of kidney cancer. The coupling of scientific advances in engineering and technology with oncological therapeutics has recently ushered a renewed optimism. The role of minimally invasive approaches through focal therapy and surgical extirpation using the robotic platform has been unprecedented and paramount. Virtual augmentation and mixed reality platforms have proved useful supplementary tools in surgical planning. The role of surgical simulation and training in development of surgeons with the optimal skill set is essential to provide optimal care. This book is the first in a series that explores the evolving trends in kidney cancer. The focus of the book is broad and includes topics ranging from immunotherapy to surgical simulation. Some chapters explore leading edge concepts while others capture the evolving trends and future concepts. The Editors aim to stimulate the readers to explore the key concepts and to encourage research and innovation along the main themes presented.

Go to the book